Edward Nirenberg on Nostr: IMO if nirsevimab access becomes truly widespread, I don't see much value in maternal ...
IMO if nirsevimab access becomes truly widespread, I don't see much value in maternal RSV vaccination over it (there are a lot of maternal vaccines). Right now, yes, it should be done because access to nirsevimab can't be guaranteed but if supply is corrected...
Published at
2024-06-28 15:59:50Event JSON
{
"id": "f5febefd46b73510239fb02554ed48b5e6d2ced230521b63d2486c2fcb19a6bc",
"pubkey": "c67b38e4c5023e985f04ae7ab6a6669cf463220e1b9ed54b897d1957004603a4",
"created_at": 1719590390,
"kind": 1,
"tags": [
[
"e",
"c8dbf02784a4679fac3f4368bec60f0641f14561fbe616e89f703044fde85dc7",
"wss://relay.mostr.pub",
"reply"
],
[
"proxy",
"https://med-mastodon.com/users/enirenberg/statuses/112695075805388845",
"activitypub"
]
],
"content": "IMO if nirsevimab access becomes truly widespread, I don't see much value in maternal RSV vaccination over it (there are a lot of maternal vaccines). Right now, yes, it should be done because access to nirsevimab can't be guaranteed but if supply is corrected...",
"sig": "13d74501c8295823868df56bdd7e4cf7a0390121a01487c7777ab673f5f911be009696dbede26d22aebd89a2cd219a50444cccc647713050ec087b4969b8db02"
}
